Introduction {#s1}
============

Bronchiectasis is a pathological dilation of the airways characterised by repeated cycles of infection and inflammation \[[@C1]\]. This airway abnormality is associated with a myriad of conditions including chronic obstructive pulmonary disease (COPD) \[[@C2]\], and linked to increased healthcare utilisation and mortality \[[@C3]\].

Subjects with other chronic airway diseases such as COPD have changes in the intraparenchymal pulmonary vessels including remodelling and pruning \[[@C4], [@C5]\]. While these changes in the pulmonary circulation might be extrapolated to smokers with bronchiectasis as they share common risk factors for bronchial and vascular injury such as smoking and inflammation, there is limited information on the intraparenchymal pulmonary circulation in adults with bronchiectasis. In an early study, R[yland]{.smallcaps} and R[eid]{.smallcaps} \[[@C6]\] demonstrated that children with cystic fibrosis, a disease characterised by the development of bronchiectasis and right ventricle hypertrophy, have fewer pulmonary arteries per unit area of lung tissue. Furthermore, a reduced calibre of the intraparenchymal arteries was documented in infants with cystic fibrosis compared to controls \[[@C7]\], a finding we have also shown in adult smokers with bronchiectasis (*versus* nonbronchiectasis subjects) on computed tomography (CT) scans \[[@C8]\]. These studies, however, did not provide data on the entire *in vivo* pulmonary vascular tree, an evaluation that is now possible to perform noninvasively using CT techniques \[[@C4], [@C9]\]. Using these techniques, the pulmonary vascular tree can be analysed and regional differences examined. The assessment of the intraparenchymal vasculature might enhance the understanding of bronchiectasis in smokers and inform potential interventions.

In this study, we used data from the COPDGene study \[[@C10]\] to quantitatively assess the intraparenchymal pulmonary vessels in smokers with radiographic bronchiectasis and test the hypothesis that this airway abnormality is associated with clinically relevant vascular pruning.

Methods {#s2}
=======

Study population {#s2a}
----------------

We used baseline data from the COPDGene study, which was designed to determine genetic and epidemiological determinants of COPD \[[@C10]\]. Briefly, current and former smokers (≥10 pack-years) aged 45--80 years were recruited to this study. Subjects with an active pulmonary disease other than COPD and asthma, and those who had an acute respiratory disease episode (*i.e.* new or increase in respiratory symptoms) within a month prior to enrolment were excluded. To test our hypothesis, we used the data from the first 500 COPDGene smokers in whom bronchiectasis scoring and pulmonary vascular data collection were performed. All subjects provided written informed consent to participate in the study. The institutional review board at each participating clinical centre approved the COPDGene study and the Partners HealthCare Research Committee (2007P-000554) approved the current study.

CT reading {#s2b}
----------

COPDGene imaging protocols were provided elsewhere \[[@C10]\]. Pertinent to this study is that the reconstruction of the volumetric images had submillimetre slice thickness, allowing a detail assessment of the bronchi. The readings were performed on baseline inspiratory CT scans by two pulmonologists with experience in lung imaging and two chest radiologists using the following steps. First, each CT was read by two primary readers independently. Bronchiectasis on CT was coded as yes, no or equivocal. A second reading was conducted on all CT scans by three primary readers. Then, all CT scans in which there were disagreements on the presence of bronchiectasis between the primary readers were assigned for a third reading to a single chest radiologist who assigned the final code. Finally, after these steps were concluded, all CTs with bronchiectasis were scored by the primary readers. Inter-reader reproducibility assessment of bronchiectasis presence and the total score was performed on 32 CT scans by the three primary readers.

Bronchiectasis definition and scoring {#s2c}
-------------------------------------

The presence of bronchiectasis was defined with one or more of the following criteria: 1) airway dilation (airway lumen diameter greater than adjacent pulmonary vessel diameter), 2) abnormal airway tapering of any extent (no decrease in or increase in lumen moving from proximal to distal airways) and 3) visualisation of a bronchus within 1 cm of the pleura. As the definition of bronchiectasis in terms of the number of locations varies, our primary definition of bronchiectasis case was defined with at least one bronchial path (*i.e.* one bronchopulmonary segment) involved. Alternate definitions used for the main analysis were as follows: 1) two or more bronchopulmonary segments involved, and 2) both criteria 2 and 3 above present. The severity of bronchiectasis was assessed using a previously used score sheet \[[@C8]\]. Briefly, the severity scoring is based on the degree of airway dilation, the type of bronchiectasis, the number of airway paths affected, and the presence of wall thickness and mucous plugging in the bronchiectatic airways. The score ranges from 1 to 40 with a greater number indicating greater severity. We use the Netter\'s bronchial path (bronchopulmonary segment) nomenclature, which has 10 and eight paths (segments) for the right and left lung, respectively \[[@C11]\]. The assessment at bronchial path level allowed us to then score bronchiectasis for the whole lung and each lobe.

Vascular morphology {#s2d}
-------------------

The methodology to identify and quantify the pulmonary vessels was described elsewhere \[[@C4], [@C9]\]. In brief, a scale-space particles method was used to segment and extract the vascular tree. The total intraparenchymal blood vessel volume (TBV) of the combined arteries and veins was determined. The distal pulmonary vasculature was determined as the aggregate volume of vessels whose cross-sectional area was \<5 mm^2^ (BV5). We used the ratio of distal to total blood vessel volume as a measure of vascular pruning (BV5/TBV×100) \[[@C4]\]. We report this metric for the whole lung and lung lobes (right upper lobe, right middle lobe, right lower lobe, left upper lobe and left lower lobe). This latter approach allowed us to compare the BV5/TBV between bronchiectatic and nonbronchiectatic lobes.

Lung volume and emphysema {#s2e}
-------------------------

Total lung volume at full inspiration was used as a radiological measure of total lung capacity (TLC~CT~) and was expressed as a percentage of predicted values \[[@C12]\]. Emphysema was measured as the percentage of low-attenuation areas below −950 Hounsfield units (%LAA~−950~) \[[@C13]\]. %LAA~−950~ is reported for the whole lung and upper and lower lobes of combined lungs. Subjects were defined as having emphysematous or nonemphysematous lungs when %LAA~−950~ of the lower third was ≥5% or \<5%, respectively \[[@C14]\].

Clinical and physiological assessments {#s2f}
--------------------------------------

Demographic and clinical data were collected with standardised questionnaires, which are available at [www.COPDGene.org](www.COPDGene.org) \[[@C10]\]. A subject was considered to have chronic heart failure and coronary artery disease if they responded "yes" to the question, "Have you ever been told by a physician that you have \[condition name\]?". Positive responses about heart attack, angina and coronary artery disease as well as self-reported history of angioplasty or coronary artery bypass surgery were collapsed into one condition named coronary artery disease. Spirometric measures of lung function were performed before and after the administration of albuterol per the American Thoracic Society recommendations. Post-bronchodilator forced expiratory volume in 1 s (FEV~1~) and forced vital capacity are presented as percentages of the predicted values \[[@C15]\]. Exercise capacity was measured using the 6-min walk test (6MWT) and prior to starting the test, resting oxygen saturation (*S*~aO~2~~) was also determined \[[@C16]\].

Statistical analysis {#s2g}
--------------------

Measurements are presented as mean±[sd]{.smallcaps} or n (%). Comparisons between smokers with and without bronchiectasis as well as those with high *versus* low CT bronchiectasis score were performed using t-test, nonparametric test or Chi-squared test as appropriate. The differences in BV5/TBV between lung lobes with and without bronchiectasis were further adjusted for potential confounders using multivariable regression analysis. Covariates for these models were chosen *a priori*, and included age, sex, race, pack-years smoked, FEV~1~ % predicted, TLC~CT~ % predicted, *S*~aO~2~,~ %LAA~−950~ on CT and coronary artery disease. To assess the association of vascular pruning with lung function and exercise capacity, four groups were created based on the presence/absence of bronchiectasis in any lobe and intraparenchymal vascular pruning (defined as the below/above median value of the aggregate BV5/TBV from both lower lobes), and their FEV~1~ and 6MWT were compared using ANCOVA as those variables did not violate normality and variances across unequal samples did not show major differences. Covariates for the FEV~1~ model were chosen *a priori*, and included age, sex, race, height, pack-years of smoking, COPD status and %LAA~−950~ of the lower lobes. A similar model was fitted for 6MWT, except that height was replaced by body mass index to account for body size. The intra- and inter-reader reproducibility for bronchiectasis diagnosis and severity score was assessed using kappa test and concordance correlation coefficients (CCCs), and Bland--Altman analysis \[[@C17], [@C18]\]. A p-value \<0.05 was considered significant. SAS 9.4 software (SAS Institute, Cary, NC, USA) was used to perform the analysis.

Results {#s3}
=======

Out of 500 subjects selected, two had an equivocal diagnosis of bronchiectasis and 12 had poor-quality vascular segmentation, leaving a sample size of 486 smokers with at least one whole-lung BV5/TBV measurement. Bronchiectasis was identified in 155 (31.9%) smokers. Compared with nonbronchiectasis subjects, those with bronchiectasis were more likely to be older and female. These subjects also had lower absolute expiratory airflows, vital capacity and 6MWT distance, with no significant differences in smoking history, cardiovascular comorbidities, resting *S*~aO~2~~, emphysema on CT scans, frequency of COPD and whole-lung BV5/TBV ([table 1](#TB1){ref-type="table"}). The primary readers 1 and 3 agreed on 88% of the CTs, yielding a kappa value of 0.72. The primary readers 1 and 2 as well as 2 and 3 agreed on 75% of the CTs, yielding a kappa value of 0.5 for both pairs. Among the cases in which the readers had an agreement, the CCC for the severity score was 0.77 (95% CI 0.55--0.99), 0.57 (95% CI 0.27--0.87) and 0.73 (95% CI 0.50--0.96) for readers 2 and 3, readers 1 and 3, and readers 2 and 3, respectively. Bland--Altman analysis did not show a systematic bias across the bronchiectasis score range among the three primary reader pairs. The results for diagnosis of bronchiectasis by reading are shown in [table E1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00044-2018.figures-only#fig-data-supplementary-materials).

###### 

Demographic and clinical characteristics of the subjects by bronchiectasis status

                                          **Subjects without bronchiectasis**   **Subjects with bronchiectasis**   **p-value**
  -------------------------------------- ------------------------------------- ---------------------------------- -------------
  **Subjects**                                            331                                 155                 
  **Age years**                                          60±9                                 64±9                  \<0.0001
  **Females**                                             57%                                 68%                     0.02
  **Non-Hispanic white race**                             78%                                 78%                     0.98
  **Height cm**                                          168±9                               166±8                    0.009
  **Body mass index kg·m^−2^**                           29±6                                 29±6                    0.86
  **Current smoking status**                              41%                                 37%                     0.33
  **Smoking history pack-years**                         45±25                               45±23                    0.93
  **Chronic heart failure**                              1.8%                                 0.7%                    0.44
  **Coronary artery disease**                             10%                                 15%                     0.12
  **FEV**~**1**~ **L**                                  2.2±0.8                             2.0±0.8                   0.006
  **FEV**~**1**~ **% predicted**                         77±24                               77±26                    0.73
  **FVC L**                                             3.3±0.9                             3.0±0.9                   0.002
  **FVC % predicted**                                    88±17                               88±19                    0.84
  **TLC**~**CT**~ **L**                                 5.5±1.4                             5.3±1.2                   0.29
  **TLC**~**CT**~ **% predicted**                        97±17                               99±14                    0.32
  **6-min walk test distance m**                        428±119                             403±117                   0.03
  **Resting *S***~**aO**~**2**~~ **%**                   96±3                                 96±3                    0.32
  **Spirometric COPD**                                    47%                                 50%                     0.52
  **Whole-lung TBV mL**                                 277±61                               275±59                   0.68
  **Whole-lung BV5 mL**                                 167±41                               164±39                   0.46
  **Whole-lung BV5/TBV %**                               60±6                                 60±7                    0.45
  **Whole-lung %LAA**~**−950**~ **%**                   6.9±9.8                             7.3±9.0                   0.72
  **Upper-lobe %LAA**~**−950**~ **%**                  7.8±10.8                             7.9±9.3                   0.90
  **Lower-lobe %LAA**~**−950**~ **%**                   5.5±8.0                             6.3±8.8                   0.31

Data are presented as mean±[sd]{.smallcaps}, unless otherwise stated. Missing data: total lung capacity determined by computed tomography (TLC~CT~), n=4; TLC~CT~ % predicted, n=4; 6-min walk test, n=2; whole-lung percentage of low-attenuation areas below −950 Hounsfield units (%LAA~−950~), n=4; %LAA~−950~ of the upper and lower lobes, n=4. FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; *S*~aO~2~~: arterial oxygen saturation; COPD: chronic obstructive pulmonary disease; TBV: total blood vessel volume; BV5: blood vessel volume in vessels \<5 mm^2^ in cross-section.

A description of the CT findings is shown in [table 2](#TB2){ref-type="table"}. Most of the subjects (94%) had cylindrical bronchiectasis and 60% had two or more lobes affected, with the right middle lobe, right lower lobe and left lower lobe being the most commonly affected. The CT severity score was significantly higher (worse) when the disease was in the lower lobes compared to upper lobes and right middle lobe combined (5.1±4.1 *versus* 2.2±1.6, p\<0.0001). Radiographic features compatible with *Mycobacterium avium* complex infection (Lady Windermere syndrome) was identified in eight (5.2%) subjects with bronchiectasis.

###### 

Description of the computed tomography (CT) findings in subjects with bronchiectasis (n=155)

  -------------------------------------------- --------------
  **Bronchiectasis type**                      
   Cylindric                                     146 (94%)
   Varicose                                        8 (5)%
   Cystic                                          1 (1%)
  **Bronchiectasis location^\#^**              
   Right upper lobe                               19 (12%)
   Right middle lobe                              97 (63%)
   Right lower lobe                               81 (52%)
   Left upper lobe                                53 (34%)
   Left lower lobe                                62 (40%)
  **Number of lobes with bronchiectasis^¶^**   
   1                                              62 (40%)
   2                                              38 (25%)
   3                                              26 (17%)
   ≥4                                             29 (19%)
  **CT bronchiectasis score median (IQR)**      3 (2.0--5.0)
  -------------------------------------------- --------------

IQR: interquartile range. ^\#^: percentages do not sum to 100% as some subjects had more than one lobe involved; ^¶^: percentages do not sum to 100% due to rounding.

Vascular pruning in bronchiectasis subjects {#s3a}
-------------------------------------------

The differences in vascular pruning were apparent in the right and left lower lobes ([table 3](#TB3){ref-type="table"} and [figure 1](#F1){ref-type="fig"}) but not in other lobes. Thus, BV5/TBV from both lower lobes were averaged and used for subsequent analysis. In adjusted models, the differences in BV5/TBV of the lower lobes remained significant ([table 4](#TB4){ref-type="table"}). Analyses in the subgroups of subjects with (n=156, 32.4%) and without emphysema (n=326, 67.6%) showed consistent results ([table 4](#TB4){ref-type="table"}). When the disease was defined as 1) bronchiectasis in two or more bronchopulmonary segments (n=94) and 2) lack of airway lumen tapering plus an airway seen within 1 cm of the pleura (n=61), the differences in BV5/TBV of the lower lobes were consistent for both the entire cohort and emphysema groups in multivariable models ([table 5](#TB5){ref-type="table"}) regardless of the definition used.

###### 

Ratio of blood vessel volume in vessels \<5 mm^2^ in cross-section (BV5) to total blood vessel volume (TBV) by lung lobe and bronchiectasis status

  **Lung lobe**            **Subjects without bronchiectasis**   **Subjects with bronchiectasis**   **p-value**
  ----------------------- ------------------------------------- ---------------------------------- -------------
  **Right upper lobe**                    64±7                                 65±8                    0.90
  **Right middle lobe**                   54±9                                54±10                    0.91
  **Right lower lobe**                    58±7                                 55±9                    0.004
  **Left upper lobe**                     62±7                                 61±7                    0.87
  **Left lower lobe**                     55±9                                51±10                   0.0008

Data are presented as mean±[sd]{.smallcaps}, unless otherwise stated. Results are from univariate comparisons of BV5/TBV×100 between subjects with bronchiectasis in a specific lobe only and those without bronchiectasis in any lobe. Missing values: one subject had no lobar vascular measurements and one subject had no vascular measurement in the right middle lobe.

###### 

Multivariable analysis for the differences in the ratio of blood vessel volume in vessels \<5 mm^2^ in cross-section (BV5) to total blood vessel volume (TBV) between subjects with lower-lobe bronchiectasis and without bronchiectasis

  **Cohort/subcohort**              **Difference in lower-lobe BV5/TBV**   **[se]{.smallcaps}**   **p-value**
  -------------------------------- -------------------------------------- ---------------------- -------------
  **Entire cohort**                                 −1.5                           0.35            \<0.0001
  **Emphysema status subcohort**                                                                 
   Subjects with emphysema                          −1.8                           0.52             0.0008
   Subjects without emphysema                       −1.6                           0.46             0.0005

The differences in lower-lobe BV5/TBV×100 are from a multivariable regression model where the presence of lower lobes bronchiectasis is the main predictor. Analyses were adjusted for age, sex, race, pack-years smoked, forced expiratory volume in 1 s % predicted, total lung capacity determined by computed tomography % predicted, resting arterial oxygen saturation, percentage of low-attenuation areas below −950 Hounsfield units (%LAA~−950~) of the lower lobes and coronary artery disease. For the analysis stratified by emphysema of the lower lobes, %LAA~−950~ was omitted as a covariate.

###### 

Multivariable analysis for the differences in the ratio of blood vessel volume in vessels \<5 mm^2^ in cross-section (BV5) to total blood vessel volume (TBV) between subjects with lower lobes bronchiectasis and without bronchiectasis using alternate definitions of the disease

  **Alternate definition**                                                      **Difference in lower-lobe BV5/TBV**   **[se]{.smallcaps}**   **p-value**
  ---------------------------------------------------------------------------- -------------------------------------- ---------------------- -------------
  **1) Two or more bronchial paths involved**                                                                                                
   Entire cohort                                                                                −1.8                           0.40            \<0.0001
   Emphysema status subcohort                                                                                                                
    Subjects with emphysema                                                                     −1.8                           0.57              0.002
    Subjects without emphysema                                                                  −1.3                           0.49              0.009
  **2) Lack of airway lumen tapering+airway seen within 1 cm of the pleura**                                                                 
   Entire cohort                                                                                −2.1                           0.58             0.0003
   Emphysema status subcohort                                                                                                                
    Subjects with emphysema                                                                     −1.9                           0.77              0.01
    Subjects without emphysema                                                                  −2.4                           0.80              0.003

The differences in lower-lobe BV5/TBV×100 are from a multivariable regression model where the presence of bronchiectasis in the lower lobes is the main predictor. Analyses were adjusted for age, sex, race, pack-years smoked, forced expiratory volume in 1 s % predicted, total lung capacity determined by computed tomography % predicted, resting arterial oxygen saturation, percentage of low-attenuation areas below −950 Hounsfield units (%LAA~−950~) of the lower lobes and coronary artery disease. For the analysis stratified by emphysema of the lower lobes, %LAA~−950~ was omitted as a covariate.

![Illustration of intraparenchymal pulmonary vascular pruning in bronchiectasis. Axial computed tomography images of the right lower lobe (RLL) from subjects a) without and b) with bronchiectasis. c and d) Three-dimensional reconstructions of the intraparenchymal pulmonary vascular tree of the right lung from the same subjects. Note the lack of pulmonary vessels in the RLL from the subject with bronchiectasis (d). e) Plot of RLL blood vessel volume to the vessel size for both subjects. Note a lower peak in blood vessel volume of small, distal pulmonary vessels in the RLL of bronchiectatic lung compared with nonbronchiectatic lung.](00044-2018.01){#F1}

Associations of regional vascular pruning with lung function and exercise capacity {#s3b}
----------------------------------------------------------------------------------

Subjects who fell into the bronchiectasis^+^/vascular pruning^+^ group had significantly lower FEV~1~ (1.70±0.70 *versus* 2.24±0.81 L, p\<0.0001) and 6MWT distance (361±122 m *versus* 441±98 m, p\<0.0001) than those falling in the bronchiectasis^+^/vascular pruning^−^ group ([figure 2](#F2){ref-type="fig"}, group 1 *versus* group 3). In adjusted models, the differences in FEV~1~ and 6MWT between those two groups remained significant (p\<0.0001 and p=0.0002, respectively). Among subjects without bronchiectasis, the differences in FEV~1~ and 6MWT between those with and without vascular pruning were also significant in univariate ([figure 2](#F2){ref-type="fig"}, group 0 *versus* group 2) and multivariable comparisons (for all comparisons p\<0.0001).

![a) Forced expiratory volume in 1 s (FEV~1~) and b) 6-min walk test (6MWT) distance by bronchiectasis in any lobe/vascular pruning in the lower lobes groups (n=485). Group 0: bronchiectasis^−^/vascular pruning^−^ (n=187); group 1: bronchiectasis^+^/vascular pruning^−^ (n=82); group 2: bronchiectasis^−^/vascular pruning^+^ (n=143); group 3: bronchiectasis^+^/vascular pruning^+^ (n=73). Note that group 3 had lower FEV~1~ and 6MWT distance than group 1. p-values are from univariate models. See the main text for the results of the adjusted models. One subject was excluded from these analyses because of a missing right lower lobe ratio of blood vessel volume in vessels \<5 mm^2^ in cross-section to total blood vessel volume, leaving a sample size of 485. The 6MWT distance measurement was missing in two additional subjects.](00044-2018.02){#F2}

Discussion {#s4}
==========

In this study, using noncontrast CT assessment of the intraparenchymal pulmonary vasculature in smokers with and without bronchiectasis, we demonstrated that 1) subjects with lower-lobe bronchiectasis have greater vascular pruning in those lobes than their nonbronchiectasis counterparts, and 2) subjects with bronchiectasis and pulmonary vascular pruning have more severe airflow obstruction and worse exercise capacity than those without pruning.

While airway abnormalities, such as dilation and thickening, as well as tortuosity and dilation of the bronchial arteries are well known pathological features of bronchiectasis, less is known about the intraparenchymal pulmonary circulation. Early studies in children with cystic fibrosis demonstrated the presence of smaller pulmonary artery calibre in cases *versus* controls and a loss of small pulmonary arteries \[[@C6], [@C7]\]. In a report of 17 adult patients who underwent surgery for bronchiectasis, a lack of perfusion in bronchiectatic lung zones was documented by pulmonary angiography and histological examination showed that "the pulmonary capillary bed was not seen" \[[@C19]\]. In adult smokers, we previously demonstrated smaller pulmonary artery diameters in vessels associated with bronchiectatic *versus* nonbronchiectatic airways \[[@C8]\]. While these findings point to a loss of intraparenchymal pulmonary vessels in bronchiectasis, further study has likely been limited but the fact that the assessments used in clinical settings are invasive or require contrast (CT angiogram). In this study, we have built on prior findings and used a noninvasive CT technique to quantify the intraparenchymal pulmonary vasculature and found that, in smokers with radiographic bronchiectasis in the lower lobes, there appears to be a loss of distal vessels. The finding suggests there might be a bronchovascular process present in mild disease as our cohort, on average, had mild radiographic bronchiectasis. Although it is not possible to identify what causes vascular pruning on CT, multiple factors, including vasoconstriction, vessel obliteration or even vessel degradation may contribute. Many of the smokers in our cohort had emphysema, a pathological feature associated with pulmonary vascular pruning. To account for emphysematous parenchymal destruction in our analyses, we used emphysema as a covariate and additionally conducted an emphysema-stratified analysis. Furthermore, we analysed vascular pruning using two additional definitions of the disease. We found that the differences in vascular pruning persisted in all those analyses, making our findings robust. We acknowledge, however, that the interplay between vascular pruning, bronchiectasis, emphysema and smoking is complex, and further research is needed to disentangle the relative contributions of these factors to vessel loss. We believe that a greater extent of this airway abnormality in addition to higher blood flow (carrying a greater burden of inflammatory mediators) in the lower lobes may partially explain the lower-lobe predominant vascular pruning observed in our cohort. This possibility is supported by our finding showing that the disease was more severe when located in the lower lobes and an observation from a prior study demonstrating that all bronchiectatic zones with a lack of perfusion were those with the more severe form of the disease \[[@C19]\].

Although our data do not provide mechanistic insight into the loss of distal vessels in bronchiectasis, we believe there are several possibilities. Subjects with stable bronchiectasis have elevated systemic inflammation \[[@C20], [@C21]\], which might cause remodelling and distortion of the vessels potentially leading to their disappearance. An additional contributor to vascular injury in this cohort is cigarette smoking exposure. A prior CT study showed a reduced cross-sectional area of pulmonary vessels in smokers without airflow obstruction \[[@C22]\]. Finally, the intraparenchymal vascular pruning we observed might be part of a more generalised vascular injury process in bronchiectasis. Recent studies of subjects with bronchiectasis have documented an increased risk of cardiovascular diseases including myocardial infarction and stroke \[[@C23], [@C24]\]. Regardless of the cause of vascular pruning, its existence may partially explain the pulmonary hypertension found in patients with severe bronchiectasis \[[@C25]\]. A large loss of small pulmonary vessels may lead to a shift in blood distribution to central, larger vessels and an increase in the pulmonary artery pressure. Our finding supports further investigation to explore the underlying mechanisms of pulmonary vascular injury in bronchiectasis and its clinical implications.

In an attempt to start to understand the clinical implications of intraparenchymal pulmonary vascular pruning in subjects with bronchiectasis, we examined the association of pruning with FEV~1~ and 6MWT. We found that those subjects with bronchiectasis and vascular pruning had reduced expiratory airflow and exercise capacity compared to those with bronchiectasis but without vascular pruning. Our findings corroborated a prior observation linking vascular pruning to lower FEV~1~ and exercise capacity in smokers with and without COPD \[[@C4]\], a disease that shares common clinical features and risk factors with bronchiectasis. Our results highlight the association of vascular loss and those outcomes in bronchiectasis beyond confounding factors such as pack-year of smoking, COPD status and emphysema.

Our study has several limitations. We used a population of heavy smokers who were enrolled into the COPDGene study because their smoking status and the presence of COPD or asthma. Thus, this sample is not representative of the entire smoking or bronchiectasis populations, and caution should be exercised when generalising these findings. However, the rich characterisation of this cohort, including volumetric CT scans allows for exploration of an understudied structure in smokers with radiographic bronchiectasis. Additionally, the particle technique employed to segment and extract the vasculature does not distinguish arteries from veins. In our modelling, we used BV5/TBV as a metric for vascular pruning; however, the process of vascular loss is likely complex and this metric might not capture this complexity. Additionally, noncontrast CT scans do not allow assessment of the bronchial circulation, so we cannot evaluate the effect of that circulation on our findings. However, since most of our subjects had only mild bronchiectasis, we believe that a bronchial circulation effect did not significantly influence our results. A visual assessment to identify bronchiectasis was used and the agreement between readers was only moderate. However, we attempted to reduce diagnosis bias by performing a three-step reading process, involving a second reading for all CTs and a third reading for those CTs in which the primary readers disagreed. We believe that the development of objective methods will likely improve our ability to accurately identify and quantify bronchiectasis.

In summary, we have demonstrated that subjects with bronchiectasis have injury beyond the airways, as demonstrated by intraparenchymal pulmonary vascular pruning. Subjects with bronchiectasis and vascular pruning have impaired expiratory airflows and exercise capacity.
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